腎細胞癌藥物研發 : 將來動向 是由出版商Espicom Business Intelligence在2010年02月所出版的。
這份英文市場調查報告書包含138 pages 價格從美金2265起跳。
腎細胞癌治療藥的銷售量在2015年將預期達到65億美金。美國、歐洲、日本的患者數在2015年也將從2008年的613,000人增加832,000人，增加了35.7％。
本報告書為腎細胞癌罹患率與治療法等的概括市場動向，到2015年為止的主力產品銷售量預測，現在與將來的產品競爭評價等，概述如以下所列。
總綱
腎細胞癌是什麼
患者統計
現在的治療法
現在的腎細胞癌市場
腎細胞癌治療藥的研究開發
將來動向
- 2015年為止的銷量預測
- 2015年的主要企業與產品
競爭分析
主要品牌分析
開發中產品分析
藥劑開發中止
附錄
Abstract
This report provides extensive analysis of the global renal cell carcinoma
market and assessment of all significant current and future products.
This is a very exciting time in the treatment of renal cell carcinoma (RCC)
With the advent of the new targeted therapies there has been a complete shift
in paradigm. Treatment options for patients with advanced disease have
improved dramatically; until recently there was limited choice and therapies
were poorly tolerated, with relatively low response rates. Patients now face
multiple options with improved safety and efficacy, and there are plenty of
further therapies in the pipeline. The overall prognosis has changed for these
patients and survival is now much longer.
While the RCC market has traditionally constituted a relatively small segment
of the oncology market, it has more recently attracted considerable R&D
investment from big pharma, biotechnology companies and specialty pharma.
Older immunotherapy regimens have now been replaced as the standard of care by
the newer targeted therapies launched in recent years, namely Pfizer' s Sutent
(sunitinib), Bayer/Onyx' Nexavar (sorafenib), Roche' s Avastin (bevacizumab)
and Pfizer' s Torisel (temsirolimus). Since the launch of these agents in
2005/2006, the RCC market has become a rapidly-growing segment, with almost
US$2.2 billion spent on branded drugs in 2008.
Significant opportunities still exist for products to expand within this
marketplace. A large percentage of patients are not currently treated with
drug therapies and are not cured by surgery alone; patients with localised and
locally-advanced disease represent a significant patient population that may
be suitable for adjuvant therapy with targeted therapies. Established agents
such as Sutent, Nexavar and Avastin are being investigated in the adjuvant
setting, along with new therapies including Wilex' Rencarex (girentuximab),
currently in Phase III trials. In addition, many patients do not respond to
current therapies, and more effective product introductions and greater use of
combination therapies will address this clinical need for patients with
metastatic RCC.
This report forecasts that sales of RCC treatments will increase substantially to almost US$6.5 billion in 2015, with a compound annual growth rate of 16.8%
The number of patients by value in the US, Europe (top five countries) and
Japan will increase by 35.7% by 2015 (from around 613,000 in 2008 to
approximately 832,000 in 2015). We estimate that approximately 18% of the RCC
patient population currently receives drug therapy. By 2015, we expect a
higher percentage of patients to receive treatment, reflecting an increase in
the number of treatment options, improvements in drug efficacy and the use of
drug therapy earlier in the course of the disease.
Why this sector is important: positive drivers
- Better US diagnosis rates: Over 30% of RCC cases in the US are diagnosed
at Stages III or IV, an area of high unmet clinical need.
- The need for improved efficacy: Around 50% of early-stage patients are not
cured by surgery and around 80% of patients with advanced disease fail to
respond to approved therapies.
- Alternative drug administration: Current immunotherapy requires frequent
administration, intramuscularly or intravenously, and the advent of
longer-acting oral products will be welcomed by clinicians and patients alike.
- More therapy choice: New treatments will gain broader indications in the
treatment of RCC eg in the adjuvant or neoadjuvant setting at earlier stages
of disease due to their proven track record of safety and efficacy.
- Improved funding: Increased accessibility to cancer drugs via Medicare
reform, Medicaid coverage and the European and Japanese regulatory health
authorities.
The shape of the RCC sector in 2008
In 2008, the RCC market was driven by sales of new targeted agents, namely
Pfizer' s Sutent (sunitinib) and Bayer/Onyx' Nexavar (sorafenib) as the clear
leaders, followed by Roche' s Avastin (bevacizumab) and Pfizer' s Torisel
(temsirolimus). Together these therapies secured sales of almost US$1.8
billion. Just five major players competed for a share of the RCC market. The
introduction of targeted therapies in 2005/2006 has seen Pfizer and Bayer/Onyx
come from nowhere to now dominate with a combined 67% market share.
...and in 2015
The total RCC sales for branded products will increase substantially from
almost US$2.2 billion in 2008, to almost US$6.5 billion in 2015, with a
compound annual growth rate of 16.8%. Sales will be driven by the new targeted
therapies which will account for sales of around US$6.1 billion in 2015, with
Pfizer' s Sutent, Bayer/Onyx' Nexavar, Roche' s Avastin and GlaxoSmithKline' s
Armala/Votrient responsible for approximately US$4.5 billion of this. There
are four current Phase III products which have the potential to reach the
market by 2015, including Wilex' Rencarex.
Table of Contents
EXECUTIVE SUMMARY
WHAT IS RENAL CELL CARCINOMA?
- Stages of the Disease
- Risk Factors
PATIENT STATISTICS
- Incidence and Mortality
- Survival and Stage at Diagnosis
PATIENT MODEL
- DRUG GROWTH DRIVERS
- DRUG GROWTH RISKS/DAMPENERS
CURRENT TREATMENTS
- Leading Brands
- Current Products' Patent Exposure
THE CURRENT RENAL CELL CARCINOMA MARKET
- PLAYERS AND PRODUCTS IN 2008
- Geographic Areas
RESEARCH & DEVELOPMENT OF RCC DRUGS
WHAT THE FUTURE HOLDS
- GLOBAL SALES FORECASTS TO 2015
- Model Assumptions
- PLAYERS AND PRODUCTS IN 2015
COMPETITOR RATIO ANALYSIS
- Competitor Ratio Analysis Criteria
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- COMPETITOR RATIO ANALYSIS - COMPANIES
- Winners and Losers
- Winners
- Losers
Analysis of Leading Brands
- Targeted Therapies
- Armala/Votrient
- Avastin
- Afinitor
- Nexavar
- Oncophage
- Sutent
- Torisel
- Immunotherapies
- Intron A
- Roferon-A
- Pegasys
- PEG-Intron
- Proleukin
Analysis Of Products Under Development
- Phase III Projects
- Anyara
- Axitinib
- Rencarex
- Tivozanib
- Phase II Projects
- Archexin
- AS1411
- Foretinib
- IMA901
- Interleukin-21
- Perifosine
- Regorafenib
- Talactoferrin alpha
- Phase I/II Projects
- AGS-003
- ImmuFact
DISCONTINUATION OF DRUGS
APPENDIX 1
Apppendix 2
Appendix 3
- Phase Transition Probability
RCC GLOSSARY
Index of Tables
- RCC Stages
- RCC Stage at Diagnosis, US
- Five-year Relative Survival Rates by Stage at Diagnosis, 1996-2004
- RCC US Population Model, 2008-2015
- RCC European Population Model, 2008-2015
- RCC Japanese Population Model, 2008-2015
- RCC Population Models, Top Seven Countries, 2008-2015
- Worldwide RCC Population Model, 2008-2015
- Summary of Standard Treatment Options for RCC
- Comparison of Leading RCC Agents
- Comparison of Recently-Launched RCC Agents
- Patent Exposure of Leading Brands
- Drugs in Development to Treat RCC
- Timeline of Selected RCC Development Projects
- Sales Forecasts of Current and Future Leading RCC Drugs (US$ millions)
- Key RCC Drugs Analysed
- Summary of Key Companies in the RCC Market by 2015
- Axitinib Treatment-Related Adverse Events
- Drugs Discontinued from Clinical Development in RCC
- Fuhrman Grading System for Renal Cell Carcinoma
- TNM Staging of Renal Cell Carcinoma
- AJCC Stage Groupings
- Probability of Launch
Index of Charts
- Schematic of Kidney
- RCC Incidence by Age at Diagnosis, UK
- Worldwide Incidence of the Major Cancers, 2008
- International Variation in RCC Incidence Rates, 2002
- RCC Incidence Rates for Selected Countries, 2002
- US Kidney Cancer Incidence Rates by Age, 1992-2006
- US Age-Adjusted Kidney Cancer Incidence Rates by Race/Ethnicity, 1992-2006
- US Kidney Cancer Mortality Rates by Age, 1992-2006
- Projected % Change in Age-Standardised RCC Mortality in the US, Europe and
Japan, 2002-2015
- RCC Mortality Rates for Selected Countries, 2002
- RCC Incidence, Top Seven Countries, 2008-2015
- RCC Mortality, Top Seven Countries, 2008-2015
- Market Share (Branded Sales) of Top Five Cancers, 2008
- Therapy Sales Split for Major Branded RCC Products, 2008
- Market Share for Major Branded RCC Products, 2008
- Market Share for Major RCC Players, 2008
- Sales Forecasts of RCC Therapies Launched in 2008 (US$ millions)
- Sales Forecasts of RCC Therapies Launched from 2009 (US$ millions)
- Therapy Sales Split for Major Branded RCC Products, 2015
- Market Share for Major Branded RCC Products, 2015
- Market Share for Major RCC Players, 2015
- Competitor Ratio Analysis Scores by Product
- Major RCC Products, 2008
- Analysis of RCC Products based on Drug Class, 2015
- Analysis of RCC Products based on Delivery, 2015
- Competitor Ratio Analysis of RCC Products Based on Company, 2015
- Votrient/Armala RCC Sales (2009E-2015E)
- Avastin Mode of Action
- Avastin RCC Sales (2008E-2015E)
- Afinitor Mode of Action
- Afinitor RCC Sales (2009E-2015E)
- Nexavar' s Dual Mode of Action
- Nexavar RCC Sales (2008E-2015E)
- Oncophage RCC Sales (2009E-2015E)
- Sutent Mode of Action
- Sutent RCC Sales (2008E-2015E)
- Torisel' s Mode of Action
- Torisel RCC Sales (2008E-2015E)
- Intron A RCC Sales (2008E-2015E)
- Roferon-A RCC Sales (2008E-2015E)
- Pegasys RCC Sales (2008E-2015E)
- PEG-Intron RCC Sales (2008E-2015E)
- Proleukin Mode of Action
- Proleukin RCC Sales (2008E-2015E)
- Anyara' s Mode of Action
- Anyara RCC Sales (2013E-2015E)
- Axitinib RCC Sales (2012E-2015E)
- Rencarex' Mode of Action
- Tivozanib RCC Sales (2013E-2015E)
- Signalling Pathways Affected by Archexin
- AS1411 Proposed Mechanism of Action
- Mode of Action of IMA901
- IL-21 Initiating Antibody-mediated Tumour Lysis
- Perifosine' s Mechanism of Action
- Talactoferrin' s Mechanism of Action in Cancer
腎細胞癌(RCC)治療藥市場的銷售額將於2015年達到65億美元
2010年03月10日
Global Information, Inc.已開始銷售著眼於調查健康護理領域的英國市場調查公司Espicom Business Intelligence所發行的報告書「Renal Cell Carcinoma Drug Discoveries: what the future holds（針對腎細胞癌的創藥：未來動向）」
腎細胞癌市場近幾年有大製藥公司、特殊醫藥品開發企業及生物工藝學企業等，對研究開發進行大規模的投資。以往的腎細胞癌治療藥市場在癌市場中，亦為較小規模的領域。Pfizer的Sutent (sunitinib)、Roche的Avastin (bevacizumab)、Pfizer的Torizel (temsirolimus)、及Bayer/Onyx的Nexavar (sorafenib) 等，自新標的療法的藥劑上市以來，急速擴大。以金額來看，2008年對治療腎細胞癌的品牌藥投資了22億美元。
從調查中可以得知，美國、歐洲主要5個國家、及日本的腎細胞癌患者數，2015年之前會增加到35.7％。更具體地說，2008年的患者數大約是61萬3,000人，預估2015年會增加到83萬2,000人。根據Espicom的預測，現在接受藥物療法者約為全部腎細胞癌患者的18％。2015年時將有更多患者會接受治療。據此可知，由於治療法的擴充與藥劑功效的改善，在該疾病的早期階段已廣泛使用藥物療法。
|
